This is the first time a partial epigenetic reprogramming therapy has entered human trials. Life Biosciences just dosed the first patient in an FDA-cleared Phase 1 study of ER-100 for optic nerve damage. The therapy delivers three reprogramming factors—OSK—via gene therapy into the eye, switched on only while the patient takes doxycycline. It comes from David Sinclair’s Harvard lab. A 2020 Nature paper showed the same approach restored vision in aged mice and a glaucoma model by resetting epigenetic marks in retinal cells. Non-human primate data later showed similar functional gains. The trial is narrow: open-angle glaucoma and NAION, safety first, roughly 18 patients, years of follow-up. It is not a whole-body age-reversal study, and claims about Alzheimer’s, ALS, or systemic reset remain unproven. Still, this is the first real clinical test of whether restoring youthful epigenetic information can improve function in living human tissue. If the eye works, the platform logic is clear: same mechanism, different organs, separate delivery problems. Most longevity ideas die in mice. This one made it into a patient. The eye is the proof point. Everything else is still a hypothesis.